American Association for Cancer Research
Browse
- No file added yet -

Figure S4 from IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance

Download (51.74 kB)
journal contribution
posted on 2023-04-14, 14:20 authored by Zoë Johnson, Chiara Tarantelli, Elisa Civanelli, Luciano Cascione, Filippo Spriano, Amy Fraser, Pritom Shah, Tyzoon Nomanbhoy, Sara Napoli, Andrea Rinaldi, Karolina Niewola-Staszkowska, Michael Lahn, Dominique Perrin, Mathias Wenes, Denis Migliorini, Francesco Bertoni, Lars van der Veen, Giusy Di Conza

Tumor experiments showing monotherapy testing of IOA-244

Funding

Innosuisse - Schweizerische Agentur für Innovationsförderung (Innosuisse)

Swiss Cancer Research Foundation (Swiss Cancer Research)

History

ARTICLE ABSTRACT

IOA-244 is a first-in-class non–ATP-competitive, PI3Kδ inhibitor with direct antitumor in vitro activity correlated with PI3Kδ expression. The ability to modulate T cells, in vivo antitumor activity in various models with limited toxicity in animal studies provides the rationale for the ongoing trials in patients with solid tumors and hematologic cancers.

Usage metrics

    Cancer Research Communications

    Categories

    Keywords

    Translational ResearchTumor MicroenvironmentPreclinical ModelsAnimal models of cancerDrug MechanismsCellular responses to anticancer drugsSmall Molecule AgentsKinase inhibitorsImmunologyImmunomodulation

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC